Regeneron (REGN) Stock Forecast & Price Target

Compare

5,066 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

REGN Analyst Ratings

Moderate Buy

17 Buy

5 Hold

1 Sell

Based on 23 analysts giving stock ratings to

Regeneron

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$753.55

▼(-3.41% Downside)

Based on 23 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $753.55 with a high forecast of $890.00 and a low forecast of $627.00. The average price target represents a -3.41% change from the last price of $780.19.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"488":"$488","891":"$891","588.75":"$588.8","689.5":"$689.5","790.25":"$790.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":890,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$890.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":753.55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$753.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$627.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[488,588.75,689.5,790.25,891],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,650.98,669.3661538461539,687.7523076923077,706.1384615384616,724.5246153846153,742.9107692307692,761.2969230769231,779.6830769230769,798.0692307692308,816.4553846153847,834.8415384615384,853.2276923076923,871.6138461538462,{"y":890,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,650.98,658.87,666.76,674.65,682.54,690.43,698.3199999999999,706.21,714.1,721.99,729.88,737.77,745.66,{"y":753.55,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,650.98,649.1353846153846,647.2907692307692,645.4461538461538,643.6015384615384,641.756923076923,639.9123076923076,638.0676923076924,636.223076923077,634.3784615384616,632.5338461538462,630.6892307692308,628.8446153846154,{"y":627,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":838.95,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":758.14,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":708.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":669.27,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":695.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":614.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":587.5,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":489.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":533.43,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":557.32,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 60,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":577.18,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":599.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 69,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$890.00

Average Price Target$753.55

Lowest Price Target$627.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Srikripa Devarakonda

Truist Financial

$812→$798

Buy

2.28%

Upside

Reiterated

11/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Louise Chen

Scotiabank

$650→$770

Hold

-1.31%

Downside

Reiterated

11/24/25

Scotiabank Reaffirms Their Hold Rating on Regeneron (REGN)

Yifeng Liu

HSBC

$890

Buy

14.07%

Upside

Initiated

11/24/25

Regeneron Buy Rating: Growth Potential Driven by Eylea HD Uptake and Oncology Catalysts

Cory Kasimov

Evercore ISI

$750

Buy

-3.87%

Downside

Reiterated

11/20/25

Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN)

Mohit Bansal

Wells Fargo

$615→$700

Hold

-10.28%

Downside

Reiterated

11/20/25

Regeneron price target raised to $700 from $615 at Wells FargoRegeneron price target raised to $700 from $615 at Wells Fargo

John Newman

Canaccord Genuity

$850

Buy

8.95%

Upside

Reiterated

11/20/25

Regeneron: Positive Developments and Strategic Investments Support Buy Rating and $850 Price Target

Geoff Meacham

Citi

$700

Buy

-10.28%

Downside

Reiterated

11/19/25

Regeneron: Strategic Positioning and Growth Potential with Eylea-HD ApprovalWe see the approvals as a positive catalyst for the Eylea franchise, enabling it to more effectively contend with the competitive anti-VEGF market. Indeed, while PFS approval is still pending, immediate impact of these approvals could drive an inflection in Eylea-HD’s performance as early as 1Q26, helping counteract prevailing headwinds (competitive dynamics, loss of funding resulting in branded market share loss, and additional biosimilars launch). Over the long term, we project the anti-VEGF market to segment into distinct niches, with Eylea-HD competing with Vabysmo and capture significant share (20-25%) of the total market. We currently model 2026/2030 Eylea-HD sales of ($2.0B/$3.2B) and combined Eylea franchise sales of ($3.8B/$3.6B). Maintain Buy, TP $700.

Evan Seigerman

BMO Capital

$725

Buy

-7.07%

Downside

Reiterated

11/19/25

Regeneron's Promising Outlook: Overcoming Regulatory Hurdles and Expanding Eylea HD's Market Potential

Carter Gould

Cantor Fitzgerald

$740

Buy

-5.15%

Downside

Reiterated

11/19/25

Cantor Fitzgerald Remains a Buy on Regeneron (REGN)

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

11/19/25

Positive Outlook for Regeneron: Buy Rating Supported by Eylea HD Approval and Strong Portfolio

William Pickering

Bernstein

$818

Buy

4.85%

Upside

Assigned

11/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (NASDAQ: REGN) and Neogen (NASDAQ: NEOG)

Terence Flynn

Morgan Stanley

$767

Buy

-1.69%

Downside

Reiterated

11/10/25

Regeneron's Innovative Anticoagulation Advancements and Market Potential Drive Buy RatingWe are approaching oral competitor pivotal data ( Exhibit 5 ); see our prior deep dive note HERE. Bayer (covered by Thibault Boutherin) is developing Asundexian (oral FXIa inhibitor), where Ph3 data in secondary stroke prevention (SSP) are expected in 4Q25. However, the drug faced a setback when the Ph3 OCEANIC-AF program was stopped early by the Data Monitoring Committee due to lack of efficacy on primary (LINK). In addition, BMY/JNJ's Milvexian is currently being evaluated in a broad Ph3 program including LIBREXIA-ACS (25mg BID) and LIBREXIA-STROKE (25mg BID) trials with data expected in 2026, and LIBREXIA-AF trial (100mg BID vs. with data expected in 2027. Further, Novartis (covered by Thibault Boutherin) is developing abelacimab in AFib (unsuitable for Morgan Stanley & Co. LLC Terence C Flynn, Ph.D.

Trung Huynh

UBS

$595→$660

Hold

-15.41%

Downside

Reiterated

11/07/25

Regeneron price target raised to $660 from $595 at UBSRegeneron price target raised to $660 from $595 at UBS

Tim Anderson

Bank of America Securities

$543→$627

Sell

-19.63%

Downside

Reiterated

10/29/25

Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks

Tyler Van Buren

TD Cowen

$780→$800

Buy

2.54%

Upside

Reiterated

10/29/25

Regeneron: Strong Financial Performance and Future Growth Potential Drive Buy RatingWe will know more by late November (the original PDUFA), as there are multiple scenarios which depend on the FDA issuing a CRL and overall flexibility.Global The COPD And CSU As discussed here, Q3 WW Dupi sales were $4.86B (+12% Q/Q; +27% Y/Y), which were 5% above consensus. Dupi continues to hold the #1 share of TRx share across all established indications (AD, asthma, CRSwNP, EoE, and PN). Demand continues to drive sales growth, with Regeneron reporting that over 1.3MM patients globally are on Dupi.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Srikripa Devarakonda

Truist Financial

$812→$798

Buy

2.28%

Upside

Reiterated

11/24/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Louise Chen

Scotiabank

$650→$770

Hold

-1.31%

Downside

Reiterated

11/24/25

Scotiabank Reaffirms Their Hold Rating on Regeneron (REGN)

Yifeng Liu

HSBC

$890

Buy

14.07%

Upside

Initiated

11/24/25

Regeneron Buy Rating: Growth Potential Driven by Eylea HD Uptake and Oncology Catalysts

Cory Kasimov

Evercore ISI

$750

Buy

-3.87%

Downside

Reiterated

11/20/25

Evercore ISI Reaffirms Their Buy Rating on Regeneron (REGN)

Mohit Bansal

Wells Fargo

$615→$700

Hold

-10.28%

Downside

Reiterated

11/20/25

Regeneron price target raised to $700 from $615 at Wells FargoRegeneron price target raised to $700 from $615 at Wells Fargo

John Newman

Canaccord Genuity

$850

Buy

8.95%

Upside

Reiterated

11/20/25

Regeneron: Positive Developments and Strategic Investments Support Buy Rating and $850 Price Target

Geoff Meacham

Citi

$700

Buy

-10.28%

Downside

Reiterated

11/19/25

Evan Seigerman

BMO Capital

$725

Buy

-7.07%

Downside

Reiterated

11/19/25

Regeneron's Promising Outlook: Overcoming Regulatory Hurdles and Expanding Eylea HD's Market Potential

Carter Gould

Cantor Fitzgerald

$740

Buy

-5.15%

Downside

Reiterated

11/19/25

Cantor Fitzgerald Remains a Buy on Regeneron (REGN)

Chris Schott

J.P. Morgan

―

Buy

―

Reiterated

11/19/25

Positive Outlook for Regeneron: Buy Rating Supported by Eylea HD Approval and Strong Portfolio

William Pickering

Bernstein

$818

Buy

4.85%

Upside

Assigned

11/19/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (NASDAQ: REGN) and Neogen (NASDAQ: NEOG)

Terence Flynn

Morgan Stanley

$767

Buy

-1.69%

Downside

Reiterated

11/10/25

Trung Huynh

UBS

$595→$660

Hold

-15.41%

Downside

Reiterated

11/07/25

Regeneron price target raised to $660 from $595 at UBSRegeneron price target raised to $660 from $595 at UBS

Tim Anderson

Bank of America Securities

$543→$627

Sell

-19.63%

Downside

Reiterated

10/29/25

Cautious Outlook on Regeneron Amid Eylea Erosion and Medicare Policy Risks

Tyler Van Buren

TD Cowen

$780→$800

Buy

2.54%

Upside

Reiterated

10/29/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month

xxx

Success Rate

14/21 ratings generated profit

Average Return

+1.31%

reiterated a xxx

rating 12 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.31% per trade.

3 Months

xxx

Success Rate

24/40 ratings generated profit

Average Return

+3.66%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +3.66% per trade.

1 Year

David RisingerLeerink Partners

Success Rate

20/25 ratings generated profit

Average Return

+18.41%

reiterated a buy rating 2 months ago

Copying David Risinger's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +18.41% per trade.

2 Years

xxx

Success Rate

20/25 ratings generated profit

Average Return

+19.59%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +19.59% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, REGN has received 59 Buy Ratings, 12 Hold Ratings, and 2 Sell Ratings. REGN average Analyst price target in the past 3 months is 753.55.

Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $10.76 with a range of $8.89 to $13.16. The previous quarter’s EPS was $11.83. REGN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.76B with a range of $3.42B to $4.11B. The previous quarter’s sales results were $3.75B. REGN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year REGN has Performed in-line its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Regeneron’s 12-month average price target is 753.55.

What is REGN’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for REGN, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is REGN a Buy, Sell or Hold?

Regeneron has a consensus rating of Moderate Buy which is based on 17 buy ratings, 5 hold ratings and 1 sell ratings.

What is Regeneron’s price target?

The average price target for Regeneron is 753.55. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $890.00 ,the lowest forecast is $627.00. The average price target represents -3.41% Decrease from the current price of $780.19.

What do analysts say about Regeneron?

Regeneron’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of REGN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Regeneron (REGN) Stock Forecast & Price Target

REGN Analyst Ratings

REGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Regeneron

REGN Analyst Recommendation Trends

REGN Financial Forecast

REGN Earnings Forecast

REGN Sales Forecast

REGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts